Pharmaceutical company
Appears in 10 stories · Last updated Nov 9, 2026
Makes risankizumab (SKYRIZI), the comparator drug in BE BOLD
Bimekizumab produced higher joint-response rates than risankizumab in psoriatic arthritis, and the gap held at every measured timepoint through Week 24. At Week 24, 54.9% of patients on bimekizumab reached ACR50 against 43.8% on risankizumab.
Updated 2 days ago
Manufacturer of Skyrizi (risankizumab-rzaa)
Since 2022, adults with moderately to severely active Crohn's disease have started Skyrizi with three intravenous infusions at weeks 0, 4 and 8, usually at a clinic. On October 23, the Food and Drug Administration approved a second path: 720 milligrams injected under the skin at weeks 0, 2, 4 and 8, given at home with an on-body injector.
Updated Nov 1
Developer of Temab-A
The FDA granted AbbVie's experimental cancer drug Temab-A two breakthrough therapy designations on October 7, one for colorectal cancer and one for non-small cell lung cancer. The designations speed development and review for drugs that show early evidence of substantial improvement over existing treatments.
Updated Oct 27
Competitor with Elahere (mirvetuximab soravtansine)
Sofetabart mipitecan (Sofe-M) plus bevacizumab shrank tumors in 23 of 29 evaluable platinum-sensitive ovarian cancer patients, a 79.3% confirmed response rate. Every patient in the Phase 1 cohort had a response or stable disease, and the rate held in patients who had already taken a PARP inhibitor.
Updated Oct 26
Co-developer and co-commercializer of epcoritamab
AbbVie and Genmab reported on October 5 that adding epcoritamab to the R-CHOP chemotherapy combination cut the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma. It is the first phase 3 trial of a bispecific antibody, a drug that steers the body's T cells onto cancer cells, to beat the 20-year-old R-CHOP backbone.
Updated Oct 24
Marketing first-approved presbyopia drop Vuity
For 240 years, reading glasses have treated presbyopia—the gradual loss of near vision that affects nearly everyone over 45—unchanged since Benjamin Franklin invented bifocals in 1785. Two billion people worldwide still rely on reading glasses today. On January 29, 2026, the FDA approved YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution), the first dual-agent eye drop for presbyopia. On October 16, 2026, the agency approved a fourth drop, RYZUMVI (phentolamine ophthalmic solution 0.75%) from Viatris, widening the market.
Updated Oct 17
As of September 2026: Owner of zumilokibart; running Phase 3 trials
Patients with moderate to severe atopic dermatitis on the mid-dose of zumilokibart hit 65.9% skin clearance at 16 weeks, versus 23.4% on placebo. AbbVie presented the Phase 2 results as a late-breaker at the European Academy of Dermatology and Venereology congress in Vienna on Sept. 30.
Updated Sep 30
As of September 2026: Entered multi-year AI drug discovery collaboration with Iambic
Iambic released Enchant v3 on September 21, 2026: a 41-billion-parameter AI model trained on 4.5 trillion tokens of biomedical data, spanning everything from protein structures to clinical trial records. The same day, AbbVie signed a multi-year deal to use the model across immunology, neuroscience, and oncology.
Updated Sep 21
As of May 2026: Co-manufacturer of venetoclax (Venclexta); submitted the supplemental new drug application
On February 20, 2026, the FDA approved venetoclax and acalabrutinib for chronic lymphocytic leukemia (CLL), the most common adult leukemia in Western countries, with roughly 23,000 new American cases each year. In a trial of 867 patients, 77% remained cancer-free at three years.
Updated May 29
As of May 2026: Decnupaz sponsor and manufacturer
The FDA approved AbbVie's Decnupaz on May 27 for blastic plasmacytoid dendritic cell neoplasm, an aggressive blood cancer. It strikes an estimated few hundred Americans a year. It's the second drug ever approved for the disease and the first doctors can start in an outpatient clinic.
Updated May 28
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
